Author Archives: adminoacido

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.

Category : Dolor

Related Articles

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.

Front Vet Sci. 2018;5:165

Authors: Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, Brown H, Berthelsen ES, Wakshlag JJ

Abstract
Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA). Methods: Single-dose pharmacokinetics was performed using two different doses of CBD enriched (2 and 8 mg/kg) oil. Thereafter, a randomized placebo-controlled, veterinarian, and owner blinded, cross-over study was conducted. Dogs received each of two treatments: CBD oil (2 mg/kg) or placebo oil every 12 h. Each treatment lasted for 4 weeks with a 2-week washout period. Baseline veterinary assessment and owner questionnaires were completed before initiating each treatment and at weeks 2 and 4. Hematology, serum chemistry and physical examinations were performed at each visit. A mixed model analysis, analyzing the change from enrollment baseline for all other time points was utilized for all variables of interest, with a p ≤ 0.05 defined as significant. Results: Pharmacokinetics revealed an elimination half-life of 4.2 h at both doses and no observable side effects. Clinically, canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity (p < 0.01) with CBD oil. Veterinary assessment showed decreased pain during CBD treatment (p < 0.02). No side effects were reported by owners, however, serum chemistry showed an increase in alkaline phosphatase during CBD treatment (p < 0.01). Clinical significance: This pharmacokinetic and clinical study suggests that 2 mg/kg of CBD twice daily can help increase comfort and activity in dogs with OA.

PMID: 30083539 [PubMed]

Powered by WPeMatico


Police probe of Brazilian marijuana researcher sparks protests.

Category : Epilepsia

Related Articles

Police probe of Brazilian marijuana researcher sparks protests.

Nature. 2018 03 15;555(7696):296

Authors: Angelo C

PMID: 29542710 [PubMed – indexed for MEDLINE]

Powered by WPeMatico


GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Category : Cancer

Related Articles

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Oncogene. 2018 Jul 30;:

Authors: Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M

Abstract
The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 40 years as very few and mostly just palliative treatments are available. As the five years survival rate remains around 5%, the identification of novel pharmacological targets and development of new therapeutic strategies are urgently needed. Here we demonstrate that inhibition of the G protein-coupled receptor GPR55, using genetic and pharmacological approaches, reduces pancreatic cancer cell growth in vitro and in vivo and we propose that this may represent a novel strategy to inhibit pancreatic ductal adenocarcinoma (PDAC) progression. Specifically, we show that genetic ablation of Gpr55 in the KRASWT/G12D/TP53WT/R172H/Pdx1-Cre+/+ (KPC) mouse model of PDAC significantly prolonged survival. Importantly, KPC mice treated with a combination of the GPR55 antagonist Cannabidiol (CBD) and gemcitabine (GEM, one of the most used drugs to treat PDAC), survived nearly three times longer compared to mice treated with vehicle or GEM alone. Mechanistically, knockdown or pharmacologic inhibition of GPR55 reduced anchorage-dependent and independent growth, cell cycle progression, activation of mitogen-activated protein kinase (MAPK) signalling and protein levels of ribonucleotide reductases in PDAC cells. Consistent with this, genetic ablation of Gpr55 reduced proliferation of tumour cells, MAPK signalling and ribonucleotide reductase M1 levels in KPC mice. Combination of CBD and GEM inhibited tumour cell proliferation in KPC mice and it opposed mechanisms involved in development of resistance to GEM in vitro and in vivo. Finally, we demonstrate that the tumour suppressor p53 regulates GPR55 protein expression through modulation of the microRNA miR34b-3p. Our results demonstrate the important role played by GPR55 downstream of p53 in PDAC progression. Moreover our data indicate that combination of CBD and GEM, both currently approved for medical use, might be tested in clinical trials as a novel promising treatment to improve PDAC patients’ outcome.

PMID: 30061636 [PubMed – as supplied by publisher]

Powered by WPeMatico


Complete Guide to Medical Marijuana for Seniors

Category : Noticias

Marijuana has had a turbulent history in the United States. Starting in the mid-1990s, however, there was a push to introduce the medical benefits of cannabis to the American people once again— ”once again,” because before the 20th century, marijuana was almost entirely legal.

Powered by WPeMatico


10 Tips for Buying Hemp-Derived CBD Products

Category : Noticias

CBD-rich hemp extracts

With Congress seemingly poised to legalize the cultivation of industrial hemp for many uses, including the production of biomass for CBD oil extraction, many questions remain unanswered. How will the DEA reschedule CBD now that Epidiolex has been approved as a pharmaceutical CBD isolate? To what extent will the FDA reguate hemp-derived CBD?

Powered by WPeMatico


CBD: My Miracle Medicine

Category : Noticias

I was born with a rare, degenerative hereditary motor and sensor neuropathy called Charcot-Marie-Tooth (CMT), a disorder of the peripheral nervous system characterized by a progressive loss of muscle tissue and touch sensation across various parts of the body. It wasn’t until I was 12 years old that I was diagnosed with Charcot-Marie-Tooth and for the following 22 years I have faced enormous challenges because of Charcot-Marie-Tooth and cannabis prohibition.

Powered by WPeMatico


Study on cannabis and chronic pain management

Category : Noticias

The University of Michigan is now conducting TWO studies on medical cannabis and we’d like you to participate!

The information you provide will help inform physicians, researchers, policy-makers, and patients about potential benefits and risks of cannabis as a therapeutic or recreational agent.

Powered by WPeMatico


A Cross-Sectional Study of Cannabidiol Users.

Category : Dolor

Related Articles

A Cross-Sectional Study of Cannabidiol Users.

Cannabis Cannabinoid Res. 2018;3(1):152-161

Authors: Corroon J, Phillips JA

Abstract
Introduction: Preclinical and clinical studies suggest that cannabidiol (CBD) found in Cannabis spp. has broad therapeutic value. CBD products can currently be purchased online, over the counter and at Cannabis-specific dispensaries throughout most of the country, despite the fact that CBD is generally deemed a Schedule I controlled substance by the U.S. Drug Enforcement Administration and renounced as a dietary supplement ingredient by the U.S. Food and Drug Administration. Consumer demand for CBD is high and growing, but few studies have examined the reasons for increasing CBD use. Materials and Methods: A self-selected convenience sample (n = 2409) was recruited via an online survey designed to characterize whom, how, and why individuals are currently using CBD. The anonymous questionnaire was accessed from October 25, 2017 to January 25, 2018. Participants were recruited through social media. Results: Almost 62% of CBD users reported using CBD to treat a medical condition. The top three medical conditions were pain, anxiety, and depression. Almost 36% of respondents reported that CBD treats their medical condition(s) “very well by itself,” while only 4.3% reported “not very well.” One out of every three users reported a nonserious adverse effect. The odds of using CBD to treat a medical condition were 1.44 (95% confidence interval, 1.16-1.79) times greater among nonregular users of Cannabis than among regular users. Conclusion: Consumers are using CBD as a specific therapy for multiple diverse medical conditions-particularly pain, anxiety, depression, and sleep disorders. These data provide a compelling rationale for further research to better understand the therapeutic potential of CBD.

PMID: 30014038 [PubMed]

Powered by WPeMatico


Anti-tumoural actions of cannabinoids.

Category : Cancer

Related Articles

Anti-tumoural actions of cannabinoids.

Br J Pharmacol. 2018 Jul 17;:

Authors: Hinz B, Ramer R

Abstract
The endocannabinoid system has emerged as a considerable target for the treatment of diverse diseases. In addition to the well-established palliative effects of cannabinoids in cancer therapy, phytocannabinoids, synthetic cannabinoid compounds as well as inhibitors of endocannabinoid degradation have attracted attention as possible systemic anticancer drugs. As a matter of fact, accumulating data from preclinical studies suggest cannabinoids elicit effects on different levels of cancer progression, comprising inhibition of proliferation, neovascularisation, invasion and chemoresistance, induction of apoptosis and autophagy as well as enhancement of tumour immune surveillance. Although the clinical use of cannabinoid receptor ligands is limited by their psychoactivity, nonpsychoactive compounds, such as cannabidiol, have gained attention due to preclinically established anticancer properties and a favourable risk-to-benefit profile. Thus, cannabinoids may complement the currently used collection of chemotherapeutics, as a broadly diversified option for cancer treatment, while counteracting some of their severe side effects.

PMID: 30019449 [PubMed – as supplied by publisher]

Powered by WPeMatico


Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines.

Category : Cancer

Related Articles

Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines.

Breast. 2018 Jun 22;41:34-41

Authors: Sultan AS, Marie MA, Sheweita SA

Abstract
Studies have emphasized an antineoplastic effect of the non-psychoactive, phyto-cannabinoid, Cannabidiol (CBD). However, the molecular mechanism underlying its antitumor activity is not fully elucidated. Herein, we have examined the effect of CBD on two different human breast cancer cell lines: the ER-positive, well differentiated, T-47D and the triple negative, poor differentiated, MDA-MB-231 cells. In both cell lines, CBD inhibited cell survival and induced apoptosis in a dose dependent manner as observed by MTT assay, morphological changes, DNA fragmentation and ELISA apoptosis assay. CBD-induced apoptosis was accompanied by down-regulation of mTOR, cyclin D1 and up-regulation and localization of PPARγ protein expression in the nuclei and cytoplasmic of the tested cells. The results suggest that CBD treatment induces an interplay among PPARγ, mTOR and cyclin D1 in favor of apoptosis induction in both ER-positive and triple negative breast cancer cells, proposing CBD as a useful treatment for different breast cancer subtypes.

PMID: 30007266 [PubMed – as supplied by publisher]

Powered by WPeMatico


Translate »